Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice

Anti-Cancer Drugs

Volumn 21, Issue 2, 2010, Pages 193-201

  Hosten, Benoît ^a,b   Abbara, Chadi ^b   Cibert, Marion ^b   Petit, Benoît ^c   Farinotti, Robert ^a   Gonin, Patrick ^c   Bonhomme Faivre, Laurence ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

BCRP; Imatinib; Interleukin 2; P gp; Pharmacokinetic resistance

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; FEMALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; FEMALE; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; PIPERAZINES; PYRIMIDINES; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 76149103239     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283349913     Document Type: Article

References (40)

1. Mignot G, Ullrich E, Bonmort M, Mé nard C, Apetoh L, Taieb J, et al. The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J Immunol 2008; 180:6477-6483.
2. Ullrich E, Mé nard C, Flament C, Terme M, Mignot G, Bonmort M, et al. Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev 2008; 19:79-92.
3. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 2002; 93:79-98.
4. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345-356.
5. Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 2000; 19:2566-2576. Review.
6. Buchdunger E, O'Reilly T, Wood J. Pharmacology of IM (STI571). Eur J Cancer 2002; 38 (Suppl 5):S28-S36.
7. Visani G, Piccaluga P, Malagola M, Isidori A. Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia. Leukemia 2009; 23:1687-1688.
8. Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, et al. IM and solid tumours. Bull Cancer 2008; 95:99-106. Review. French.
9. Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, et al. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 2007; 97:735-740.
10. Breedveld P, Beijnen JH, Schellens JHM. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006; 27:17-24.
11. Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcg1a) on the transport of IM mesylate (Gleevecs) across the mouse blood-brain barrier. J Neurochem 2007; 102:1749-1757.
12. Declè ves X, Bihorel S, Debray M, Yousif S, Camenisch G, Scherrmann JM. ABC transporters and the accumulation of IM and its active metabolite CGP74588 in rat C6 glioma cells. Pharmacol Res 2008; 57:214-222.
13. Schinkel AH, Mayer U,Wagenaar E, Mol CA, Van Deemter L, Smit JJ, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoprotein. Proc Natl Acad Sci U S A 1997; 94:4028-4033.
14. Kimura Y, Aoki J, Kohno M, Ooka H, Tsuruo T, Nakanishi O. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol 2002; 49:322-328.
15. Burger H, Nooter K. Pharmacokinetic resistance to IM mestlyate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle 2004; 3:1502-1505.
16. Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005; 55:379-386.
17. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, et al. Pharmacokinetics and pharmacodynamic of IM in a phase 1 trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22:935-942.
18. Kruijtzer CMF, Beijnen JH, Schellens JHM. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. The Oncologist 2002; 7:516-530.
19. Burger H, Tolvan H, Brok M, Wiemer EA, Bruijn EA, Guetens G, et al. Chronic IM mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCG1 (MDR1) drug transport pumps. Cancer Biol Ther 2005; 4:747-752.
20. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008; 112:2024-2027.
21. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109:3496-3499.
22. Enk AH, Nashan D, Rübben A, Knop J. High dose inhalation interleukin-2 therapy for lung metastasis in patients with malignant melanoma. Cancer 2000; 88:2042-2046.
23. Stein U, Wather W, Schoemaker RH. Modulation of Mdr 1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br J Cancer 1996; 74:1384-1391. (Pubitemid 26370728)
24. Veau C, Faivre L, Tardivel S, Soursac M, Banide H, Lacour B, et al. Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. J Pharmacol Exp Ther 2002; 302:742-750. (Pubitemid 34787243)
25. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50:3473-3486.
26. Shah VP, Midha KK, Dighe SV. Workshop report. Pharm Res 1992; 9:588-592.
27. Burtin P, Mentre F, Van Bree J, Steimer JL. Sparse sampling for assessment of drug exposure in toxicological studies. Eur J Drug Metab Pharmacokinet 1996; 21:105-111.
28. Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 1988; 16:303-309.
29. Hamada H, Miyano H,Watanabe H, Saito H. Interaction of IM mesilate with human P-glycoprotein. J Pharmacol Exp Ther 2003; 307:824-828.
30. Daoudaki M, Fouzas I, Stapf V, Ekmekcioglu C, Imvrios G, Andoniadis A, et al. Cyclosporine a augments P-glycoprotein expression in the regenerating rat liver. Biol Pharm Bull 2003; 26:303-307.
31. Koziolek MJ, Riess R, Geiger H, Thévenod F, Hauser IA. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int 2001; 60:156-166.
32. Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, Schellens JH. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 2009; 27:31-40.
33. Hosten B, Abbara C, Petit B, Dauvin A, Bourasset F, Farinotti R, et al. Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice. Drug Metab Dispos 2008; 36:1729-1735.
34. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83:258-264.
35. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-566.
36. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-1037.
37. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, et al.; IRIS (International Randomized Interferon vs. STI571) Study Group. IM pharmacokinetics and its correlation with response and safety in chronicphase chronic myeloid leukemia: a sub analysis of the IRIS study. Blood 2008; 111:4022-4028.
38. Hosten B, Challuau D, Gil S, Bouquet C, Marion S, Perricaudet M, et al. Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma. Anticancer Drugs 2006; 17:195-199.
39. Akira S, Kishimoto T. NF-IL6 and NF-kappa B in cytokine gene regulation. Adv Immunol 1997; 65:1-46. Review.
40. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003; 22:90-97.